Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Simplified Consent for HIV Vaccine Trials
This study has been completed.
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT00105339
  Purpose

The main goal of this project is to develop and evaluate a simplified version of an HIV vaccine trial consent form designed for high-risk adolescents. The process will include: (1) reducing reading grade level by simplifying sentence structure and decreasing the use of infrequently used words; (2) re-organizing and categorizing the material for improved flow; and (3) developing a set of pictures to emphasize key concepts in the material. These materials will be tested among small focus groups of high-risk adolescents. A pre-post test design will be used to compare the simplified, adolescent-tailored consent form to one currently used in the National Institute of Allergy and Infection Diseases (NIAID) Vaccine Trial Information Booklet.


Condition Intervention
Adolescent
Vulnerable Populations
Behavioral: Simplified prototype consent form
Behavioral: Standard prototype consent form

MedlinePlus related topics: AIDS
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Simplified Consent for HIV Vaccine Trials

Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 255
Study Start Date: December 2003
Study Completion Date: February 2004
Primary Completion Date: February 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 Behavioral: Simplified prototype consent form
2 Behavioral: Standard prototype consent form

Detailed Description:

In the United States, there has already been widespread preparation for the HIV vaccine efficacy trials. Since the first HIV vaccine trial enrolled volunteers in 1988, there have been numerous clinical trials of different vaccine candidates studied through NIAID's vaccine evaluation program. Since the outcome of a prophylactic HIV vaccine trial depends in part on the compliance of volunteers, one major effort that has been made is to determine the readiness of several high-risk populations to participate in vaccine trials. Numerous studies on the feasibility and willingness to participate in an adult HIV vaccine trial have already been conducted.

Increased willingness to participate has been found to be associated with high-risk behaviors, lower education level, and being uninsured or covered by public insurance, as well as higher HIV incidence rates. Baseline knowledge of vaccine trial concepts was low among all of the populations studied.

One population for which a vaccine could be extremely efficacious is high-risk adolescents-- who face a lifetime of dealing with a chronic illness if infected with HIV. Adolescents at risk for HIV and therefore eligible and in need of a vaccine are likely to be low-income, poorly educated, and a disenfranchised population. Moreover, they are likely to have below-average reading and verbal comprehension skills, and difficulty with medical terminology. Issues of literacy and comprehension of informed consent become even more critical when dealing with populations with special vulnerabilities. To achieve truly informed consent for vaccine trials, Hodel (1994) has insisted that further research is crucial in determining what information is meaningful to potential participants in order for them to decide whether to participate. Potential HIV vaccine participants must fully understand complex concepts (e.g., that a person will test positive for HIV, even though they do not have the virus--they are "vaccine positive").

Children and adolescents have developmental limitations on their abilities to comprehend information. With some exceptions, the majority of IRBs require parental consent for research involving minors. Typically, parent or guardian permission for research on minors may not be solicited for research with substantially greater than minimal risk unless there is direct benefit to the minor with a risk-benefit ratio at least as good as available alternatives. There are also special considerations for involvement of adolescents in research where needs of parents and of the adolescents may conflict in terms of concerns about privacy.

Studies have suggested that simplifying the language and using short sentences have enhanced understanding. Other studies support the use of visual aids to enhance adolescent understanding and to enable adolescents to give truly informed consent.

The aims of the project are to randomize adolescents at risk for HIV to either a simplified adolescent-friendly prototype condition, or to the standard condition in order to determine:

  1. if adolescents assigned to the simplified, adolescent-tailored prototype condition have significantly better comprehension scores than those assigned to the standard condition;
  2. if adolescents assigned to the simplified, adolescent-tailored prototype condition have significantly better recall scores than those assigned to the standard condition;
  3. if willingness to participate in a vaccine trial is significantly different among adolescents assigned to the simplified condition compared to the standard condition.
  Eligibility

Ages Eligible for Study:   15 Years to 19 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A sample of high-risk adolescents from 3 ATU sites will be recruited for both sets of focus groups, the Illustration Style Preference Group (n = 30; 10 per site) and the Review of Draft Groups (n = 45; 15 per site), and for the Comprehension/Recall Trial (n = 180; 60 per site), for total of 255 participants.

Criteria

Inclusion Criteria:

  • Ages 15 to 19 years (self identified)
  • At risk for HIV/AIDS as determined by responses to an anonymous screen for sexual risk
  • Giving assent or consent, depending on age
  • English-speaking

Exclusion Criteria:

  • Non-English speaking
  • Not shown to be at risk through use of screener
  • Unwilling/unable to provide informed consent/assent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00105339

Locations
United States, California
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90054-0700
United States, Florida
Children's Diagnostic and Treatment Center
Fort Lauderdale, Florida, United States, 33301
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10128
Sponsors and Collaborators
Investigators
Study Chair: Debra Murphy, PhD Adolescent Trials Network
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: Adolescent Trials Network ( Debra Murphy, PhD )
Study ID Numbers: ATN 006
Study First Received: March 11, 2005
Last Updated: March 18, 2008
ClinicalTrials.gov Identifier: NCT00105339  
Health Authority: United States: Federal Government

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
consent form, vaccine trial
Simplified consent form

Study placed in the following topic categories:
HIV Infections
Acquired Immunodeficiency Syndrome

ClinicalTrials.gov processed this record on January 16, 2009